ライフサイエンスコーパス: base treatment

1 such as solvent polarity, concentration, and base treatment.

2 tive intramolecular 1,5-H shift pathway upon base treatment.

3 inhibits the current conventional microbial-based treatment.

4 in artery and branches, and 42 to ultrasound-based treatment.

5 s (HCV) infection and response to interferon-based treatment.

6 ith a greater likelihood of response to cell-based treatment.

7 and tissue disruption by means of cavitation-based treatment.

8 receiving NNRTI-based and 20 receiving LPV/r-based treatment.

9 rameters and fewer dyslipidemia AEs than EFV-based treatment.

10 sis and 58% had received previous interferon-based treatment.

11 ist treatment (OAT) during and following DAA-based treatment.

12 ained virologic response to prior interferon-based treatment.

13 are highly desirable to facilitate evidence-based treatment.

14 ial for clinical implementation of dosimetry-based treatment.

15 unosuppressive regimen with conventional CNI-based treatment.

16 carcinoma are often ineligible for cisplatin-based treatments.

17 ow for the use of personalized, biologically based treatments.

18 sibility of more precise mechanism-of-action-based treatments.

19 n, and may facilitate clinical trials of tau-based treatments.

20 studying cell behaviour under different drug-based treatments.

21 d lead to the development of novel mechanism-based treatments.

22 he treatment may be an alternative to photon-based treatments.

23 atments are also needed to identify evidence-based treatments.

24 ceptor protein by traditional pharmaceutical-based treatments.

25 assessing other chemotherapies or radiation-based treatments.

26 their high prevalence and lack of mechanism-based treatments.

27 ilitate the development of improved antibody-based treatments.

28 ral veterans from engaging in these evidence-based treatments.

29 each of these classes of selective antibody-based treatments.

30 nsplant practices rather than immunoglobulin-based treatments.

31 for in vitro studies and as a source of cell-based treatments.

32 patients who are ineligible for fludarabine-based treatments.

33 that FAAH inhibitors may aid fear extinction-based treatments.

34 that systematically use these other evidence-based treatments.

35 arch lines in the search for effective plant-based treatments.

36 with outcome was relevant for immunotherapy-based treatments.

37 seling and future enrollment in gene therapy-based treatments.

38 %) were retired, 87 (41%) were on castration-based treatment, 19 (9%) had received chemotherapy, and

39 [605/713], P < 0.001), and for those on EFV-based treatment (60% [12/20] vs 86% [214/248], P = 0.002

40 % [214/248], P = 0.002) and for those on DTG-based treatment (61/92 [66%] vs 84% [391/465] P < 0.001,

41 roups have followed the paradigm of response-based treatment adaptation and toxicity sparing through

42 nt state and remaining challenges of imaging-based treatment adaptation in radiation oncology.

43 luR5 may be a promising target for mechanism-based treatments aimed at mitigating this disorder.

44 thy, have been characterized and an evidence-based treatment algorithm is available.

45 We provide a consensus-based treatment algorithm, based on clinical presentatio

46 effectively limit the extent to which ozone-based treatment alone can produce recycled water for gro

47 an also be readily regenerated via mild acid/base treatment and maintain constant boron adsorption ca

48 the synthesis, including high sensitivity to base treatment and the instability of glycopeptides with

49 (AST) technologies that will enable evidence-based treatment and promote antimicrobial stewardship.

50 d clinical trials indicate that transference-based treatments and alternative treatments work equally

51 e summarize core principles of mentalization-based treatments and preventive interventions and the ev

52 e III trial comparing different lenalidomide-based treatments and received induction with lenalidomid

53 Clinical trials to support evidence-based treatments and the development of disease-specific

54 sorders, our results suggest that metabolism-based treatments and/or metabolic substrates might repre

55 F pathology and the efforts to develop miRNA-based treatments and/or to consider miRNAs as biomarkers

56 tcomes, causes and pathophysiology, evidence-based treatment, and a call for action.

57 water using membrane-based treatment, ozone-based treatment, and hybrid treatment trains comprising

58 e thrombolytic treatment as well as catheter-based treatment, and results from recent trials in the s

59 rldwide, who received primary amphotericin B-based treatment, and were analysed for day-42 all-cause

60 f smoke inhalation injury, the best evidence-based treatments, and challenges and future directions i

61 son engagement session, delivery of evidence-based treatments, and regular follow-up by master's leve

62 ure directions include the use of new immune-based treatments (antibodies or cellular-based therapies

63 d has implications for research and computer-based treatment applications.

64 TE, a comprehensive, multidisciplinary, team-based treatment approach for first-episode psychosis des

65 fter stroke, providing an effective evidence-based treatment approach in this population.

66 Community-based treatment approaches are important to reduce the a

67 These data support development of eCB-based treatment approaches for mood and anxiety disorder

68 prior relapser patients receiving telaprevir-based treatment are eligible for shorter, 24-week total

69 Efficacious medication-based treatments are available and widely used, often al

70 ) is a hematological cancer for which immune-based treatments are currently in development.

71 However, mAb-based treatments are not always successful, highlighting

72 For genotype 1, sofosbuvir-based treatments are not cost-effective compared to Viek

73 he origins of PCOS remain unknown, mechanism-based treatments are not feasible and current management

74 Current anti-MPM chemotherapy-based treatments are only marginally effective, and long

75 oaches, such as vaccines and oncolytic virus-based treatments-are being investigated.

76 athway, which suggests the potential for APC-based treatment as a strategy for structural repair in t

77 criminal justice agencies received evidence-based treatment at lower rates than women referred throu

78 or development and testing of novel evidence-based treatments, both trauma-focused and non-trauma-foc

79 There is no evidence-based treatment, but various systemic immunomodulating t

80 is similar to historic rates with interferon-based treatment, but with shorter treatment duration and

81 ent decreases the efficacy of these antibody-based treatments, but neutralization sensitivity often c

82 to streamline the investigation of genotype-based treatments by screening tumours for multiple genom

83 Guideline-based treatment can improve outcomes in AF.

84 The chemical-based treatment can lead to environmental pollution, so

85 cell culture to animals in which microtubule-based treatments can be tested and compared with one ano

86 We aimed to evaluate the guideline-based treatment costs by DAAs from the perspective of th

87 the requisite health status data on which to base treatment decisions would help ensure that older pa

88 utcome information is needed to inform value-based treatment decisions for advanced-stage NSCLC.

89 convened a public workshop titled "Evidence-Based Treatment Decisions in Transplantation: The Right

90 sult of treatment can vary between patients, basing treatment decisions for individual patients on th

91 The increasing popularity of antibody-based treatment demands a better understanding of antibo

92 at underlie relapse is critical for evidence-based treatment development.

93 mean rank 56.6 [SEM 4.5] vs 68.3 [4.5]; rank-based treatment difference -11.7, 95% CI -24.3 to 0.96;

94 with scaling up multiple structured evidence-based treatments (EBTs), a transdiagnostic treatment cou

95 1.1 [SD 1.2] vs 4.1 [3.4] mean events, model-based treatment effect -2.9 [95% CI -3.5 to -2.3]; p<0.0

96 We study the resulting Lasso-based treatment effect estimator under the Neyman-Rubin

97 ovide a roadmap to develop a single antibody-based treatment effective against multiple Ebolavirus in

98 reasons for valvular surgery because no drug-based treatments exist.

99 anage both vascularized PEDs, where evidence-based treatment exists, and nonvascularized PEDs, where

100 Family-based treatment (FBT) is an evidence-based therapy for a

101 d could constitute a novel neurobiologically-based treatment for a seemingly change-resistant group o

102 al trials of high-dose intravenous ascorbate-based treatment for cancer.

103 Fluoroquinolone-based treatment for contacts with presumed DR-TB infecti

104 Bone marrow cell (BMC)-based treatment for critical limb ischemia in diabetic p

105 Integrating evidenced-based treatment for depression with evidenced-based adhe

106 n conditions, showing promise as a materials-based treatment for early-stage osteoarthritis.

107 ntibody cocktail ZMapp is a promising immune-based treatment for Ebola virus disease (EVD).

108 t step towards a new generation of stem cell-based treatment for heart failure.

109 However, when considering a device-based treatment for hypertension, the underlying pathoph

110 behavioural therapy (CBT)-the best evidence-based treatment for insomnia-has not been tested in this

111 Although urban-rural disparities in evidence-based treatment for myocardial infarction in China have

112 Mexiletine is the first evidence-based treatment for nondystrophic myotonias.

113 ffects of a nonanthracycline and trastuzumab-based treatment for patients with early-stage human epid

114 mab has potential application as an evidence-based treatment for patients with NMOSD.

115 nitive processing therapy (CPT), an evidence-based treatment for posttraumatic stress disorder (PTSD)

116 l mechanism for expanding access to evidence-based treatment for pregnant women in the US.

117 eption of azithromycin, there is no evidence-based treatment for primary ciliary dyskinesia; therapie

118 Bright light therapy is an evidence-based treatment for seasonal depression, but there is li

119 WHO recommends hospital-based treatment for young infants aged 0-59 days with cl

120 offer renewed hope for development of IL-12-based treatments for cancer.

121 ained virologic response (SVR) to interferon-based treatments for chronic hepatitis C virus infection

122 l be paramount for designing novel mechanism-based treatments for circumventing chemotherapy-induced

123 s, and undermine efforts to develop evidence-based treatments for COVID-19.

124 des a valuable opportunity to test stem cell-based treatments for dental disorders.

125 ich has the potential to advance cannabinoid-based treatments for drug addiction.

126 Cannabis-based treatments for epilepsy have generated much intere

127 k, and the increased application of evidence-based treatments for established coronary heart disease.

128 There is a conspicuous paucity of evidence-based treatments for FNS.

129 Sofosbuvir-based treatments for genotype 1 in general are not cost-

130 However, interferon-based treatments for HCV infection have significant toxi

131 nerative endodontic procedures are stem cell-based treatments for immature teeth with pulp necrosis.

132 ays suppressed by BCL6 and suggest mechanism-based treatments for lymphoma.

133 Evidence-based treatments for major depressive disorder (MDD) are

134 Evidence-based treatments for metastatic, human epidermal growth

135 Evidence-based treatments for metastatic, human epidermal growth

136 ct should be considered when designing IGF-1-based treatments for neurodegenerative diseases.

137 vides a molecular basis for developing light-based treatments for obesity and its related metabolic d

138 They focused on medication-based treatments for OIC, but also recommended lifestyle

139 omized clinical trials have studied evidence-based treatments for OVC in low-resource settings.

140 Cannabis-based treatments for pain and spasticity in patients wit

141 d may be a suitable adjuvant in nanoparticle-based treatments for PDAC.

142 who have poor adherence to existing evidence-based treatments for posttraumatic stress disorder (PTSD

143 ed and emerging pharmacotherapies and device-based treatments for posttraumatic stress disorder that

144 s article offers (a) an overview of evidence-based treatments for PTSD, (b) a description of a transl

145 c kidney disease, but there are few evidence-based treatments for reducing cardiovascular events in t

146 s and were managed for 1 year with algorithm-based treatments for rhinitis and asthma.

147 l and efficient development of new glutamate-based treatments for SCZ.

148 ion by age 18 years yet few receive evidence-based treatments for their depression.

149 indings might be used for developing microbe-based treatments for these disorders.

150 Several methotrexate (MTX) based treatments (free MTX, MTX loaded Lecithin-PVA nano

151 at determine the outcome of an immunotherapy-based treatment from a physical point of view; (i) space

152 paper, we discuss the evolution of catheter-based treatment from first-generation thrombectomy devic

153 vinyl substituted bis-propargyl ethers upon base treatment generally form phthalans via the Garratt-

154 2) to 13.8% (10.5-17.0) in the annual school-based treatment group, 17.9% (13.7-22.1) to 8.0% (6.0-10

155 rsus historic patients who had undergone tPE-based treatment (group B, n = 56).

156 is needed to develop evidence and consensus-based treatment guidelines for each subgroup, and requir

157 are warranted in order to formulate evidence-based treatment guidelines for patients with cerebellar

158 RATIONALE: The development of evidence-based treatment guidelines for pediatric pulmonary arter

159 Adherence to evidence-based treatment guidelines in rectal cancer is suboptima

160 dgment in situations not covered by evidence-based treatment guidelines.

161 rent treatment practices lag behind evidence-based treatment guidelines.

162 s on meta-analyses and contemporary evidence-based treatment guidelines.

163 Although opioid-based treatment has been the cornerstone of pain relief,

164 Guideline-based treatment has dramatically improved the outcomes o

165 ieve adequate disease control with rituximab-based treatment have few treatment options and a poor pr

166 Immune-based treatments have been approved for clinical use in

167 Nucleic acid (NA)-based treatments hold great potential to combat outbreak

168 tive improvement in vision after bevacizumab-based treatment in children with OPGs.

169 ht the therapeutic potential of an anti-PD-1-based treatment in promoting the reinvigoration of T cel

170 because of high levels of empirical-evidence-based treatment in smear-negative patients.

171 Despite many reports of putative stem-cell-based treatments in genetic and degenerative disorders o

172 Peg-IFN-based treatment induced a stronger decrease in the HBV R

173 In the present study, we found that a miRNA-based treatment inhibiting miRNA-34a (miR-34a) was more

174 Parent-based treatment is a viable model to provide weight loss

175 Sofosbuvir-based treatment is cost-effective for incarcerated perso

176 riability in patient outcome after rituximab-based treatment is partly explained by rituximab concent

177 Failure of interferon (IFN)-alpha-based treatment is related to host immunity.

178 h good school enrolment, we find that school-based treatment is sufficient for achieving EPHP.

179 o fail directly-acting antiviral agent (DAA)-based treatment is unknown.

180 ations, the identification of a generic gene-based treatment is urgently needed.

181 e goal of reliably delivering effective gene-based treatments is now in sight.

182 In addition to cornea-based treatment, long-term studies of a hyperopic phakic

183 ggests that a combination of SU and incretin-based treatment may be efficacious in patients with HNF1

184 lue to drug and nondrug rewards, novel brain-based treatments may finally be on the horizon.

185 Thus, apoptotic-EV-based treatment might be a promising therapeutic approac

186 This Minireview will focus on nanoparticle-based treatment modalities that can induce and enhance I

187 Photodynamic therapy (PDT) is a light-based treatment modality that has exhibited safety and e

188 ication of an emerging electrochemical redox based treatment modality.

189 a mineralocorticoid receptor (MR) antagonist-based treatment model to reduce cardiovascular risk in p

190 Base treatment of the N-tosylated products provides an e

191 rated with a Rose Bengal sensitiser, for SDT-based treatment of a pancreatic cancer model (BxPc-3) in

192 Algorithm-based treatment of acne by primary care clinicians may e

193 first systematic report on cyclophosphamide-based treatment of acute AMR based on modern diagnostics

194 L cells are a target of GVHD and that GLP-2-based treatment of acute GVHD restores intestinal homeos

195 n support of IL1RAP as a target for antibody-based treatment of AML.

196 urs slowly and limits the potential for cell-based treatment of demyelinating disease.

197 recommendations to provide ART prior to IFN-based treatment of HCV and may provide insights into the

198 Current interferon alpha-based treatment of hepatitis C virus (HCV) infection fai

199 h hypertension is common in CKD and evidence-based treatment of hypertension has changed considerably

200 rdiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholest

201 additional option for approaching community-based treatment of mental health problems.

202 that CD46 is a promising target for antibody-based treatment of multiple myeloma, especially in patie

203 Strategies for FGF signalling-based treatment of osteoarthritis and for cartilage repa

204 etic resonance (MR) cholangiopancreatography-based treatment of patients with possible choledocholith

205 biological questions and effective evidence-based treatment of patients with these inherited mutatio

206 Long-term efficacy of catheter-based treatment of persistent atrial fibrillation is uns

207 on a case of late HBV reactivation after DAA-based treatment of recurrent hepatitis C in an antibody

208 mutational scanning data using a likelihood-based treatment of the mutation counts.

209 efficacy of a reduced RUTF dose in community-based treatment of uncomplicated SAM.

210 thway as a potential target for novel immune-based treatments of chronic fungal disease.

211 d hormones (T(3) and T(4)), and the HPG axis-based treatments of estrogen replacement therapy, the pr

212 ceptor antagonist mifepristone, the HPT axis-based treatments of thyroid hormones (T(3) and T(4)), an

213 seful strategy for improving reconsolidation-based treatments of traumatic memories associated with a

214 ed therapies might provide a novel mechanism-based treatment option for patients with persistent PTH.

215 A transcatheter-based treatment option for severe TR appears safe and fe

216 syndrome and there are very limited evidence-based treatment options available.

217 pathophysiology, translation into mechanism-based treatment options is lacking.

218 frailty, furthering advancements in evidence-based treatment options, and identifying cost-effective

219 across these rare diseases with few evidence-based treatment options.

220 It requires chemical-based treatment or enzymatic hydrolysis to cleave the ch

221 ing capabilities constitute potential immune-based treatments or prophylaxis against hepatitis C viru

222 (1) producing recycled water using membrane-based treatment, ozone-based treatment, and hybrid treat

223 However, parent-based treatment (PBT), which is provided to the parent w

224 e potential to enable comprehensive evidence-based treatment plans to be implemented quickly, rather

225 A high-intensity, lifestyle-based treatment program for obesity delivered in an unde

226 High-quality evidence supporting a community-based treatment protocol for children with severe acute

227 and can be used to inform novel biologically based treatment protocols for patients with medulloblast

228 prices, targeted testing and liver fibrosis-based treatment provided worse outcomes at higher cost o

229 ences from placebo exceeded the MID, and ICS-based treatments provided the greatest improvements.

230 ility were randomized to different community-based treatment providers trained to provide rectal arte

231 nd laboratory data would facilitate etiology-based treatment rather than relying on empirical treatme

232 in view of the paucity of data and evidence-based treatment recommendations are missing.

233 MRI-based treatment recommendations were compared against fi

234 o were receiving a bedaquiline- or delamanid-based treatment regimen.

235 Georgia receiving a bedaquiline or delamanid-based treatment regimen.

236 to enhance the effectiveness of these immune-based treatment regimens.

237 We observed a high rate of SVR 12 with SOF-based treatment regimes, however probably due to the hig

238 Cell-based treatment represents a new generation in the evolu

239 .09) for patients receiving NNRTI- and LPV/r-based treatment, respectively.

240 arameters, overall survival (OS), and RECIST-based treatment response were tested by Cox and logistic

241 In sensitivity analysis, fibrosis-based treatment restrictions were cost-effective at prev

242 Base treatment resulted in hierarchical porosity and inc

243 Bortezomib-based treatment resulted in a strong decrease of renal d

244 ment, improved prognostication, and evidence-based treatment selection.

245 Exposure-based treatments share the aim of facilitating or restor

246 l immunomodulation and direct microbial kill-based treatment shortening regimens for drug-susceptible

247 proximal, large-vessel occlusions, IA device-based treatment should be initiated in patients with sma

248 Evidence-based treatments should be available to these individual

249 clobutane ring was able to tolerate acid and base treatments showing good chemical stability.

250 MFCLs are one evidence-based treatment shown to be effective in slowing myopia

251 mpered the clinical translation of microglia-based treatments shown to be effective in animal disease

252 fication, and open new avenues for archetype-based treatment strategies and clinical trials optimizat

253 Here, we discuss how nanomedicine-based treatment strategies are well suited to immunother

254 line IPI are the most cost-effective, immune-based treatment strategies for metastatic melanoma.

255 (epidermal growth factor receptor) antibody based treatment strategies have been successfully implem

256 bilitation set-ups towards personalized home-based treatment strategies, by adopting novel technologi

257 clinical applications of SMDs- and antibody-based treatment strategies, their limitations and challe

258 or effective tailoring of perfusion pressure-based treatment strategies.

259 g risk to patients and when determining risk-based treatment strategies.

260 forefront of the development of novel immune-based treatment strategies.

261 pt for repurposing mibefradil as a mechanism-based treatment strategy for GBM.

262 A PET-based treatment stratification is applicable clinically

263 After induction treatment, MRD-based treatment stratification resulted in excellent sur

264 and sooner, than those treated with evidence-based treatments such as methadone, suggesting that CDDC

265 and sooner, than those treated with evidence-based treatments such as methadone, suggesting that CDDC

266 clinicians should offer or arrange evidence-based treatment, such as medication-assisted treatment w

267 dividuals do not respond to current evidence-based treatment, suggesting a critical need for new inte

268 to receive albendazole through annual school-based treatment targeting 2-14 year olds or annual or bi

269 ical, intra-articular, regenerative medicine-based treatment technique for focal cartilage defects of

270 ly had lower rates of response to interferon-based treatment than patients of other races.

271 Evidence-based treatments that achieve optimal energy intake and

272 s provide support for future neuroplasticity-based treatments that take into account both the sensory

273 Relative to annual school-based treatment, the risk ratio for annual community-wid

274 ffer cost-effective alternatives to membrane-based treatment, the standard process for potable reuse

275 patients do not achieve SVR with telaprevir-based treatment, their viral population is often signifi

276 Base treatment then affords a protected pseudodisacchari

277 Despite effective, evidence-based treatments, there is significant individual variab

278 ung age would not have met current guideline-based treatment thresholds for statin therapy prior to t

279 anagement and shed light on current evidence-based treatments through a 'new' algorithmic approach, e

280 limitations, we employ the use of a chemical-based treatment to deplete phagocytic immune cells in An

281 er registries are needed to provide evidence-based treatments to improve in-hospital outcome.

282 While the membrane-based treatment train exhibits economies of scale, we de

283 Ozone-based treatment trains comprising ozone and biologically

284 and the association of testing with evidence-based treatment using a mineralocorticoid receptor antag

285 The cost efficacy of PET- versus CT-based treatment was also calculated.

286 Parent-based treatment was as effective on child weight loss an

287 The ICER of sofosbuvir-based treatment was less than $100,000 per QALY in cirrh

288 e needing treatment, but in whom fludarabine-based treatment was not possible.

289 Nevertheless, relative to membrane-based treatment, we identify opportunities for ozone-bas

290 In China, evidence-based treatments were provided less often in 2001 in rur

291 of cancer, who received a fluoropyrimidines-based treatment, were retrospectively genotyped in the D

292 reviewed to identify the effect of community-based treatment when returning inmates into the general

293 important with the switch from chemotherapy-based treatments, which trade control of CLL with furthe

294 biomarker studies indicate that bevacizumab-based treatment-while reducing blood flow, volume, and p

295 and hybrid treatment trains comprising ozone-based treatment with a membrane sidestream, and (2) deli

296 was associated with higher rates of evidence-based treatment with MRAs and better longitudinal BP con

297 lus lifestyle modification), medical therapy-based treatment with revascularization only for patients

298 ookworm prevalence and intensity than school-based treatment, with little additional benefit of treat

299 better care for allergies based on guideline-based treatment would allow Europe's economy substantial

300 sed DSA clearance compared with historic tPE-based treatment, yet spontaneous clearance of new DSA al